BioNTech founders plan to launch new venture Arife amid a dispute over patents, compensation, and employee futures with their former company
Executive summary: Ugur Sahin and Özlem Türeci revealed plans to establish a new company, Arife, leading to a dispute with BioNTech over patents, money, and employee futures. The outcome could affect BioNTech's intellectual property portfolio, staff morale, and the founders' ability to advance their own mRNA ventures.
Who is involved: Ugur Sahin, Özlem Türeci, BioNTech SE, its employees, and the newly proposed entity Arife.
Likely next: Negotiations or legal proceedings concerning patent rights and separation terms are expected to unfold in the coming weeks.
The founders of BioNTech, Ugur Sahin and Özlem Türeci, have disclosed plans to establish a new venture named Arife, a move that has ignited a conflict with their former employer over the ownership of key mRNA patents, the terms of financial compensation, and the future of employees who might transfer to the new company. BioNTech has stated its intention to safeguard its core technology and maintain workforce stability, while the founders emphasize their desire to pursue independent projects. Commentary in the Handelsblatt notes that the launch of Arife is viewed as a positive development for the German biotech location, and reports indicate that an experienced industry figure may assume a seat on the new company’s board. This situation places important intellectual property assets at the center of a negotiation that could shape how mRNA innovations are shared or licensed between the two entities. The outcome will also affect talent retention, as decisions about employee transfers and compensation packages may influence morale and recruitment efforts in the sector. In the near term, the focus is likely to settle the dispute over patent rights and employee arrangements, which will determine the immediate operational scope of Arife and the extent to which BioNTech can preserve its existing R&D momentum and competitive positioning in the rapidly evolving mRNA therapeutics market.
What's next — scenarios
Base: negotiated settlement (50%)
Founders retain a limited license to key patents; BioNTech keeps core IP; employee transfers are settled.
- settlement talks conclude
- joint press release issued
- regulatory filing of license agreement
Upside: founders win full patent rights (30%)
Arife gains exclusive rights to core mRNA patents, boosting its valuation and potentially reducing BioNTech's revenue streams.
- patent office awards priority to founders
- court ruling favoring Arife
- investment round for Arife announced
Downside: prolonged litigation (20%)
Legal battle delays Arife's launch, increases costs for both parties, and creates uncertainty for employees and investors.
- lawsuit filed in German patent court
- injunction requested on patent use
- appeals process extends beyond 2027
Timeline
- — Pharma: „Enteignung der eigenen Firma“ – Eklat um das Erbe von Biontech (Handelsblatt)
- — Kommentar: Die neue Firma der Biontech-Gründer ist eine gute Nachricht für den Standort D (Handelsblatt)
- — Biotechnologie: Biontech-Gründer starten neue Firma in Deutschland – ein alter Bekannter soll Vorstand werden (Handelsblatt)
Analysis — what this means
Sectors affected
- Biotechnology
Key entities
Sources
- Pharma: „Enteignung der eigenen Firma“ – Eklat um das Erbe von Biontech — Handelsblatt
- Pharma: „Enteignung der eigenen Firma“ – Eklat um das Erbe von Biontech — Handelsblatt
- Kommentar: Die neue Firma der Biontech-Gründer ist eine gute Nachricht für den Standort D — Handelsblatt
- Biotechnologie: Biontech-Gründer starten neue Firma in Deutschland – ein alter Bekannter soll Vorstand werden — Handelsblatt
- Biotechnologie: Biontech-Gründer starten neue Firma in Deutschland – ein alter Bekannter soll Vorstand werden — Handelsblatt
Related cases
- BioNTech founders launch a new German biotech venture, signaling continued entrepreneurial drive in mRNA innovation
- BioNTech founders launch new venture Arife, sparking dispute over patents, finances and staff future
- German Federal Finance Court confirms inheritance tax liability even when heirs receive no assets
- German Federal Fiscal Court clarifies that inheritance tax liability remains even if the heir receives no actual assets
- German inheritance tax liability persists even when heirs receive no assets, affecting estate liquidity and planning
- Employees can obtain tax‑free reimbursement for private charging of company electric cars if they document the electricity used